| HRA010802
(Controlled Access)
|
Patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (nCRT) were enrolled in this molecular residual disease (MRD) study. Baseline tumor tissue samples and serial blood samples were collected (baseline, post-nCRT [CRE-1 and CRE-2], and post-surgery [1 month, F1; and 3-to-6 months, F2]). This study assessed the feasibility of circulating tumor DNA (ctDNA) in detecting residual disease after nCRT to improve the selection of patients for a watch-and-wait strategy and stratification of postsurgical recurrence risk to guide adjuvant treatment. |
